Patients with high expression of KIF21B have been demonstrated to have a poorer prognosis in hepatocellular carcinoma (Zhao et al., 2020) and non-small cell lung cancer (Sun et al., 2020). This evidence concerns the gene KIF21B and non-small cell lung carcinoma.